TIA & Stroke Facts and Information

“I didn’t know 1 in 6 people who have a TIA (“mini-stroke”) will have a stroke within 90 days.” Learn more about TIA.

AGGRENOX may help.

AGGRENOX is proven more effective than low-dose aspirin alone at reducing your risk of a subsequent stroke following a TIA (transient ischemic attack or “mini-stroke”). Get the facts.

“My doctor told me that up to 42% of men and 24% of women who've had a stroke will have another one within 5 years.” Learn more about a subsequent stroke.

AGGRENOX may help.

AGGRENOX is the only FDA-approved combination prescription medication indicated to reduce the risk of a stroke following a stroke due to a blood clot. Get the facts.

“If there’s an effective treatment that may help my loved one reduce their risk of a stroke, I want to know.” Learn more about caring for someone who has had a TIA or stroke.

AGGRENOX may help.

AGGRENOX combines two antiplatelets, low-dose aspirin and extended-release dipyridamole, to reduce the risk of formation of a blood clot—and thereby helps to reduce the risk of a subsequent stroke following a TIA or stroke due to a blood clot. Get the facts.

This flash element is not visible because you do not have Adobe^® Flash Player 9. Click here to download the latest version free of charge. This link is provided to you as a convenience. Boehringer Ingelheim Pharmaceuticals, Inc. does not control, and is not responsible for, the content of any linked page.

For new AGGRENOX patients A FREE Trial Offer Get a 30-Day FREE Trial Offer* of AGGRENOX.
*60 capsules

Taking AGGRENOX? We’re here for you. Join the Taking Smart Steps™ program for tips, education, and savings!

Are you a caregiver? Look for special caregiver notes on this site marked with the caregiver heart symbol.

Need Help paying for AGGRENOX? Our patient assistance program may be able to help. Boehringer Ingelheim CARES FOUNDATION

Important Safety Information

AGGRENOX is a prescription medication used to lower the risk of stroke in people who have had a “mini-stroke” (transient ischemia attack or TIA) or stroke due to a blood clot.

AGGRENOX should be avoided in patients allergic to any ingredient in AGGRENOX, allergic to non-steroidal anti-inflammatory drugs (NSAIDS), or who have the combination of asthma, runny nose and nasal polyps. AGGRENOX should not be given to a child or teenager due to the risk of Reye’s syndrome.

AGGRENOX may cause an increased bleeding risk, including into the brain, stomach or intestines and any bleeding may take longer to stop. AGGRENOX should be avoided in patients with a history of stomach ulcers or those who drink three or more alcoholic drinks a day due to the risk of bleeding. Patients should inform their doctor of all medications they are currently taking including NSAIDS or blood thinners.

AGGRENOX should be avoided during pregnancy, especially in the third trimester, or in patients with severe liver or kidney problems. The most common side effects of AGGRENOX are headache, upset stomach and diarrhea.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

Click here for full Prescribing Information, including Patient Information.